Actively Recruiting
MRD Monitoring in Lung Cancer After Resection
Led by Guangdong Provincial People's Hospital · Updated on 2022-03-17
300
Participants Needed
1
Research Sites
330 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The conception of molecular residual disease (MRD) extending from hematologic tumor to solid tumors. Evidences supporting MRD evaluation for lung cancer by liquid biopsy has gradually accumulated, especially circulating tumor DNA (ctDNA). In this observational study, the investigators prospectively enroll stage I-IIIA non-small cell lung cancer (NSCLC) patients who underwent complete resection. Preoperative blood sample, tumor tissue and dynamic postoperative blood samples are collected continuously for MRD detection. This study aim to explore the prognostic value of MRD for stage I-IIIA NSCLC patients after complete resection.
CONDITIONS
Official Title
MRD Monitoring in Lung Cancer After Resection
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosis of histologically confirmed NSCLC (WHO 2015 classification) with resectable (stage I-IIIA) disease
- Complete resection
- Age �3D 18 years at the time of screening
- Capable of giving signed informed consent
You will not qualify if you...
- Mixed small cell and NSCLC histology
- Rx, R1 or R2 resection
- History of other malignant tumors within 5 years
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Guangdong Lung Cancer Institute & Guangdong Provincial People's Hospital
Guangzhou, Guangdong, China, 510030
Actively Recruiting
Research Team
X
Xue-Ning Yang, Ph.D
CONTACT
J
Jia-Tao Zhang, Ph.D
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here